Federal Contractor Profile
Venatorx Pharmaceuticals INC
Federal contracting record: $299M obligated across 7 awards from 2 agencies, FY 2016–2026.
$299M
Total Obligated
7
Award Records
2
Agencies Served
3
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
MBBKNBU5DCC6
CAGE Code
61SY9
Address
30 SPRING MILL DR, MALVERN, PA, 193551200
First Federal Award
Oct 20, 2015
Most Recent Award
Jul 31, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$284M
95.1% of total obligations
- Department of Defense$15M
4.9% of total obligations
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Jul 31, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $256K |
| Aug 27, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $7.0M |
| Aug 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $370K |
| Jul 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $9.4M |
| Sep 15, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $20M |
| Jul 11, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $8.4M |
| Jun 7, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $3.3M |
| May 16, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $4.7M |
| Sep 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS | $72M |
| Sep 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $5.0M |
| Sep 16, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $4.5M |
| Jun 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $9.5M |
| May 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $3.0M |
| Mar 4, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $2.3M |
| Sep 16, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $4.0M |
| Aug 13, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $16M |
| May 12, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $6.3M |
| Apr 22, 2021 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.9M |
| Apr 15, 2021 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.0M |
| Mar 9, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $440K |
| Sep 23, 2020 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541711 | PENICILLIN BINDING PROTEINS IGF::OT::IGF | $1.0M |
| Sep 3, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $1.9M |
| Jun 29, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $3.2M |
| Apr 22, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. | $1.2M |
| Apr 20, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS, INC. | $23M |
Want to win work like Venatorx Pharmaceuticals INC?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.